In 2022, COVAX’s efforts targeting long-term COVID-19 impact and beyond, transitioned into the “mRNA Technology Transfer Programme”, convened by WHO and its partner Medicines Patent Pool (MPP). Five Working Groups (WG) are responsible for the design and coordination of the activities required to fulfill the objectives of the mRNA Technology Transfer Programme.
|Working Group 1 – Technology selection, technical innovation, and IP|
|Working Group 2 – Product development, including clinical development, Manufacturing and Technology Transfer|
|Working Group 3 – Regulatory strengthening: support the development of regulatory capabilities and skilled workforce to facilitate regional approvals.|
|Working Group 4 – Business Modelling & Market shaping strategies/ policies|
|Working Group 5 – Programme Funding & Governance|
A Scientific and Technical Review Committee (STeRCO) of independent experts and stakeholders supports the WHO secretariat on aspects of critical importance to the successful accomplishment of the objectives of the mRNA Technology Transfer Programme.
Additionally, a mRNA Scientific Advisory Committee (mSAC) convened by MPP comprising of experts in mRNA vaccine development provides technical input into the programme.
The mRNA Technology Transfer Programme operates in close cooperation with the Biomanufacturing training initiative coordinated by WHO and the WHO Academy, to align training needs for both hub and partners (manufacturing, good practices, technology transfer) and training offer.
The Scientific and Technical Review Committee (STeRCO) supports the mRNA Technology Transfer Programme to realize the vision of improving health and health security in low- and middle-income countries through sustainable, regional production of mRNA vaccines.
The function of the Scientific and Technical Review Committee is to support the programme on the following areas:
- Strategic directions, including the technology(ies) to implement and transfer,
- the preclinical and clinical development plans as needed for technology(ies) of interest
- compliance to the regulatory guidelines
- value for money regarding allocation of funds
- other issues of critical importance to the successful accomplishment of the goals of the programme.
The STeRCO shall provide support to WHO Secretariat in consideration of potential programme expansion.
Scientific and Technical Review Committee Current Members
The mRNA Scientific Advisory Committee (mSAC) is an independent committee convened by the Medicines Patent Pool (MPP) to deliver answers, on a consultative basis, to specific questions on scientific matters addressed to them relating to the mRNA Technology Transfer Hub Programme.
mRNA Scientific Advisory Committee Members: